OphthalmoPharma

OphthalmoPharma AG is a Swiss pharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The company focuses on addressing unmet medical needs in eye care through the optimization of established active pharmaceutical ingredients and the development of specialized treatments for rare ocular diseases. Its portfolio includes therapies for dry eye disease, glaucoma, and corneal cross-linking, as well as a dedicated program for ocular cystinosis. OphthalmoPharma emphasizes the production of preservative-free formulations to improve patient tolerability and long-term eye health. The company is headquartered in Sarnen, Switzerland, and operates with a lean, expert-driven business model.